Tirzepatide Associated With Lower Risk of Diabetic Retinopathy Progression and Treatment
A retrospective study published in Ophthalmology indicates that patients with diabetes who take tirzepatide show a lower risk of diabetic retinopathy progression compared to those using lifestyle interventions alone. While the findings are promising, researchers emphasize that the study shows an association rather than direct causation.
Why it matters
This research provides important clinical insights into the secondary benefits of weight-loss and diabetes medications for ocular health.
Patients with diabetes who initiated tirzepatide had lower rates of diabetic retinopathy, vision-threatening complications, and retinal interventions than matched patients receiving lifestyle intervention alone, according to a large retrospective study published in Ophthalmology. 1
The findings suggest that tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, may have a different ocular risk profile than has been reported with some other rapidly acting glucose-lowering medications. However, the researchers say the observational study establishes an association and does not demonstrate that tirzepatide directly protects against diabetic retinopathy.
Investigators used the TriNetX US Collaborative Network to identify patients with diabetes and overweight or obesity who initiated tirzepatide. These patients were propensity score matched with individuals who received lifestyle interventions, such as nutrition therapy or exercise counseling, but had not been exposed to weight-loss medications.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in